New cocktail of drugs aims to keep HER2+ breast cancer in check
NCT ID NCT07610720
First seen May 30, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This Phase 2 trial is testing whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can help keep advanced breast cancer from growing. It involves 57 women with HR+/HER2+ metastatic breast cancer whose disease has not worsened after initial treatment. The study measures how long participants live without their cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District
RECRUITINGGuangdong, GUANGZHOU, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dalpiciclib (a CDK4/6 inhibitor) combined with trastuzumab, pertuzumab, pyrotinib, and endocrine therapy (letrozole, anastrozole, exemestane, or fulvestrant)
What this could lead to
If successful, this could offer a new first-line maintenance treatment option to delay cancer progression in people with HR+/HER2+ metastatic breast cancer.
What could go wrong
This is a small Phase 2 trial with only 57 participants, so results may not apply to everyone. Side effects from the drug combination, such as diarrhea, are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.